Exhibit 99.3
 
The unaudited pro forma information below gives effect to the share exchange between Camp Nine, Inc. and Relmada Therapeutics, Inc.  as if it had been consummated as of December 31, 2013.  The unaudited pro forma information has been derived from the historical Financial Statements of these two companies.  The unaudited pro forma information is for illustrative purposes only.  You should not rely on the unaudited pro forma financial information as being indicative of the historical results that would have been achieved had the acquisition occurred in the past or the future financial results that the Company will achieve after the merger.

Camp Nine, Inc. and Relmada Therapeutics, Inc.
Pro Forma Combined Statements of Operations
(Unaudited)
 
   
As of
February 28, 2014
    
As of
December 31, 2013
                  
   
Camp Nine,
Inc.
    
Relmada
Therapeutics,
Inc.
        
Pro Forma Adjustments
    
Pro Forma Combined
  
Assets
                            
Current assets:
                            
Cash and cash equivalents
   $ 2,626     $ 3,522,450   (5 )   $ 2,626     $ 3,527,702  
Prepaid expenses
             10,325                   10,325  
Inventory
     6124           (5 )     (6,124 )     -  
Deferred financing costs, net of amortization of $69,546
             78,724   (3 )     (78,724 )     0  
                                     
Total current assets
     8,750       3,611,499           (82,222 )   $ 3,538,027  
                                     
Fixed assets, net of accumulated depreciation of $550 and $373, respectively
     1,250       8,498   (5 )     (1,250 )     8,498  
Other assets
             12,100                   12,100  
                                     
Total assets
   $ 10,000     $ 3,632,097           (83,472 )   $ 3,558,625  
                                     
Liabilities and Stockholders’ Deficit
                                    
                                     
Current liabilities:
                                    
Accounts payable
   $ 41,155     $ 180,319   (5 )     (41,155 )     180,319  
Accrued expenses
     -       438,658   (3 )     (33,305 )     405,353  
Derivative liabilities
     -       20,103,425   (4 )             20,103,425  
Subordinated promissory notes payable, net  
     -       758,951   (3 )     (758,951 )     -  
                                     
Total current liabilities
     41,155       21,481,353           (833,411 )     20,689,097  
                                     
Long-term liability – accrued expense
     0       100,000           -       100,000  
                                     
Total liabilities
     41,155       21,581,353           (833,411 )   $ 20,789,097  
                                     
Commitments and contingencies
                                    
                                     
Stockholders’ deficit:
                                    
Series A preferred stock, 0, 1,360,413 and 0 issued, outstanding and pro forma, respectively
     -       1,360   (1 )     (1,360 )     -  
Common stock, $0.001 par value, 90,000,000 shares authorized, 28,500,000, 4,958,777, 23,026,693 issued, outstanding and pro forma, respectively
     28,500       4,959   (1 )     (10,432 )     23,027  
Additional paid-in capital
     15,000       16027084   (1 )(2)(5)     687,077       16,729,161  
Deficit accumulated during the development stage
     (74,655 )     (33,982,659 )  (2 )(3)     74,655       (33,982,659 )
                                     
Total stockholders’ deficit
     (31,155 )     (17,949,256 )         749,940       (17,230,471 )
                                     
Total liabilities and stockholders’ deficit
   $ 10,000     $ 3,632,097           (83,472 )   $ 3,558,625  
 
Pro forma footnotes:
 
(1)
To record 100% of Relmada Therapeutics, Inc.’s fully diluted shares in exchange for 80% of Camp Nine, Inc. shares.
   
(2)
To eliminate accumulated deficit during the development stage of Camp Nine, Inc.
   
(3)
To eliminate deferred financing fees, accrued interest and subordinated debt that were associated the common stock that was recorded to additional to paid-in-capital as a result of a merger with Camp Nine, Inc.
   
(4)
Does not reflect the reclassification of the derivative liabilities to additional paid-in-capital, upon the merger with Camp Nine.
   
(5)
To eliminate all assets and accrued expenses of Camp Nine Inc. upon the reverse merger.  Relmada Therapeutics, Inc. is not assuming any assets nor any liabilities in this merger.
   
(6)
Gives effect to a retroactive share exchange whereby  the shareholders of Relmada Therapeutics, Inc. exchanged ten shares of common shares and received one common share of Camp Nine common stock.

 
 
 
 
The unaudited pro forma information below gives effect to the share exchange between Camp Nine, Inc. and Relmada Therapeutics, Inc.( the "Company") as if it had been consummated as of the beginning of the applicable period.  The unaudited pro forma information has been derived from the historical Financial Statements of these two companies.  The unaudited pro forma information is for illustrative purposes only.  You should not rely on the unaudited pro forma financial information as being indicative of the historical results that would have been achieved had the acquisition occurred in the past or the future financial results that the Company will achieve after the merger.

Camp Nine, Inc. and Relmada Therapeutics, Inc.
Pro Forma Combines Statements of Operations
(Unaudited)
 
   
For the Three Months Ended
                
   
February 28,
2014
    
March 31,
2014
                
   
Camp Nine,
Inc.
    
Relmada
Therapeutics,
Inc.
      
Pro Forma Adjustments
    
Combined
  
                           
Product revenues
   $ 682     $ -       $ -     $ 682  
Cost of goods sold
     685       -         -       685  
Gross profit (loss)
     (3 )     -         -       (3 )
                                   
Operating expenses:
                                  
General and administrative
     (3,121 )     (496,103 ) (2)      500       (498,724 )
Research and development
     -       (215,793 )       -       (215,793 )
Total operating expenses
     (3,121 )     (711,896 )               (715,017 )
                                   
Loss from operations
     (3,124 )     (711,896 )       (500 )     (715,520 )
                                   
Other income (expenses):
                                  
Change in fair value of derivative liabilities
     -       7,329,526         -       7,329,526  
Interest income
     -       -         -       -  
Interest expense
     -       (123,800 )  (1)     123,800       -  
Total other expenses
     -       7,205,726         123,800       7,329,526  
                                   
Net (loss) income
   $ (3,124 )   $ 6,493,830       $ 123,300     $ 6,614,006  
                                   
Net loss (income ) per common share - basic
   $ (0.00 )   $ 1.30               $ 0.33  
                                   
Net loss (income ) per common share - diluted
   $ (0.00 )   $ 0.31               $ 0.30  
Weighted average number of common shares outstanding - basic
     28,500,000       4,983,511                 19,754,270  
                                   
Weighted average number of common shares outstanding - diluted
     28,500,000       20,960,697                 22,127,329  

(1)
To eliminate expenses of notes including accrued interest, debt discounts as if the transaction occurred at the beginning of the period.
   
(2)
Elimination of depreciation expense since the Camp Nine, Inc. assets are not being assumed by the Company.
   
(3)
Gives effect to a retroactive share exchange whereby  the shareholders of Relmada Therapeutics, Inc. exchanged ten shares of common shares and received one common share of Camp Nine common stock.
 
 
2
 
 
The unaudited pro forma information below gives effect to the share exchange between Camp Nine, Inc. and Relmada Therapeutics, Inc. (the "Company) as if it had been consummated as of the beginning of the applicable period.  The unaudited pro forma information has been derived from the historical Financial Statements of these two companies.  The unaudited pro forma information is for illustrative purposes only.  You should not rely on the unaudited pro forma financial information as being indicative of the historical results that would have been achieved had the acquisition occurred in the past or the future financial results that the Company will achieve after the merger.

Camp Nine, Inc. and Relmada Therapeutics, Inc.
Pro Forma Combined Statements of Operations
(Unaudited)
 
   
For the Years Ended
                
   
February 28, 2014
    
December 31, 2013
                
   
Camp Nine,
Inc
    
Relmada
Therapeutic,
Inc.
    
Pro Forma Adjustments
      
Pro Forma Combined
  
                           
Product revenues
   $ 3,166     $ -     $ -       $ 3,166  
Cost of goods sold
     2,693       -       -         2,693  
Gross profit
     473       -       -         473  
                                   
Operating expenses:
                                  
General and administrative
    (49,820 )   $ (1,525,257.00 )     500   (2 )   (1,574,577 )
Research and development
    -       (5,248,669 )     -         (5,248,669 )
Total operating expenses
     (49,820 )     (6,773,926 )     500         (6,823,246 )
                                -  
Loss from operations
     (49,347 )     (6,773,926 )               (6,823,273 )
                                -  
Other income (expenses):
                                  
Change in fair value of derivative liabilities
    -       (12,877,675 )               (12,877,675 )
Interest income
     -       -                 -  
Interest expense
     -       (220,307 )     220,307   (1 )   (220,307 )
Total other expenses
     -       (13,097,982 )     220,307         (13,097,982 )
                                   
Net loss
  $ (49,347 )   $ (19,871,908 )   $ 220,307       $ (19,700,948 )
                                   
Net loss per common share - basic and diluted
   $ (0.00 )   $ (0.82 )             $ (0.86 )
                                   
Weighted average number of common shares outstanding - basic and diluted
     26,636,986       24,292,670                 23,026,693  

(1)
To eliminate expenses of notes including accrued interest, debt discounts as if the transaction occurred at the beginning of the period.
   
(2)
To eliminate depreciation expense since the Camp Nine assets are not being assumed by the Company.
   
(3)
Gives effect to a retroactive share exchange whereby  the shareholders of Relmada Therapeutics, Inc. exchanged ten shares of common shares and received one common share of Camp Nine common stock.

3